Q1 FY27 results: Revenue up 9.5%, PAT falls 47%, exceptional items weigh

Exceptional ItemEbitda Margin CompressionResults View source PDF Explain this filing

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.2%Reaction day

₹532.70

prior close

₹546.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-9.5% vs market

Pharmaceuticals peers, median of 165sector-0.6%-8.6% vs sector

On the reaction day the stock moved 9.5 pts less than Nifty Microcap 250 and 8.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.1

10m

-6.3

15m

-7.0

30m

-7.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.2+0.4-9.5-0.6-8.6

Next day

-7.7+0.5-8.3-0.3-7.4

-7.8+0.6-8.4-0.6-7.2

-7.4+0.7-8.1-1.4-6.0

-8.3+1.1-9.4-1.1-7.2

-6.3+0.5-6.8-1.9-4.4

+0.1+1.3-1.2-1.4+1.5

15d

-6.0+0.5-6.6-0.9-5.1

-8.7-0.8-7.9-0.2-8.5

-5.2-0.9-4.3-3.2-2.0

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 revenue rose 9.5% YoY to INR 102.97 cr but PAT fell 47% to INR 4.37 cr. EBITDA margins compressed from 13.8% to 7.8%. An exceptional item of INR 2.03 cr for lease rent added to the pain. Final dividend announced with record date Sept 11, 2026. 89th AGM on Sept 23, 2026 via video call. Auditors issued unmodified review report.

Likely market impact

Weak quarter with sharp profit decline and margin pressure despite revenue growth. Exceptional charges and regulatory costs weighed on earnings.